---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-010481"
form_type: "8-K"
ticker: "ARTV"
cik: "0001817241"
company_name: "Artiva Biotherapeutics, Inc."
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T07:14:07.048257+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Artiva appoints Daniel Baker to board; forms Clinical Strategy Committee

## Summary
- Daniel Baker, Ph.D. appointed as Class I director effective Jan 28, 2025; term expires at 2025 annual meeting.
- Baker also named to Clinical Strategy Committee; Laura Bessen, Brian Daniels, Laural Stoppel appointed as members; Diego Miralles as chair.
- Baker receives $40K annual board retainer and initial option for 27,500 shares; one-third vested immediately, remainder over two years.
- Clinical Strategy Committee members get $7,500 annual retainer; chair receives $15,000.

## SEC filing metadata
- accession: 0000950170-25-010481
- form_type: 8-K
- ticker: ARTV
- cik: 0001817241
- company_name: Artiva Biotherapeutics, Inc.
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817241/000095017025010481/0000950170-25-010481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817241/000095017025010481/artv-20250128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-010481
- JSON: https://secwatch.observer/filing/0000950170-25-010481.json
- Plain text: https://secwatch.observer/filing/0000950170-25-010481.txt

## Key facts
- Executive change
  Daniel Baker was appointed as Class I Director at Artiva Biotherapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On January 28, 2025, the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel Baker, Ph.D. as (i) a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817241/000095017025010481/0000950170-25-010481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.